|Re-excision rates of periocular basal cell carcinoma|| |
|Wong Y.L.1, Kopsidas K.2|
|1Manchester Royal Eye Hospital, Ophthalmology, Manchester, United Kingdom, 2Stepping Hill Hospital, Stockport, United Kingdom|
|Introduction: Basal cell carcinoma (BCC) is the most common malignant tumor of the eyelid. Although it rarely metastasizes, BCC can cause clinically significant local destruction. The mainstay treatment and prevention of recurrence for BCC is by complete excision.|
Purpose: The main aim of this study is to determine the number of patients requiring re-excision, their reasons and to determine how many were unnecessary.
Methods: Retrospective study of 119 patients with a histological diagnosis of Periocular BCC between 2016 -2018 in the Ophthalmology Department, Stepping Hill Hospital. List of patients was obtained from the histopathology lab.
Results: Of the 119 patients from October 2015 to October 2018, 66 were female and 53 were male. The youngest patient is of age 26 and the oldest 98 years old; with the mean age of 71.3. The most common site is the lower lid followed by canthus, brow and finally upper lid. The most common histological subtype is nodular (n=58) and the rarest being nodulocystic (n=2). 89 patients had staged excisions locally, 27 patients were referred for Moh's micrographic surgery in Salford Royal Infirmary Hospital and the remaining 3 had biopsies only. Of the 89 patients with staged excisions, 15/89 (17%) required a re-excision. Reasons for re-excision include tumour extending to nearest margin (8/15) and a narrow margin (7/15). Amongst patients with re-excision, majority were lateral canthal lesions with infiltrative nodular histological subtype. Only 1 patient with staged excision had a recurrence (1/89). The recurrence was an infiltrative nodular right lower lid BCC with a nearest margin of 0.25mm. No recurrence following Moh's micrographic surgery was noted in this patient group.
Conclusions: Re-excision is more common in BCC with an infiltrative histological subtype. Majority 13/15(87%) of the surgical re-excision is tumour free. It is recommended that patients with infiltrative BCC referred for a MMS.
Dr Yee Ling Wong , Manchester Royal Eye Hospital , Manchester , United Kingdom
Assigned in sessions:
16.06.2019, 10:00-11:30, Free Papers/Rapid Fire, FP15, Oculoplastics, Refractive Surgery, Galliéni 1+2